Clinical Trials Sponsored by Creabilis SA

Total 1014 results

Aktiia SA

Not yet recruiting

Evaluation of the Satisfaction of a Hypertensive Population in Their Use of the Aktiia 24/7 Blood Pressure Monitor (OBPM_HTN2024)

Hypertension
Aesyra SA

Recruiting

Efficacy of AesyBite Active in Reducing Sleep Bruxism Activity

Sleep Bruxism

Italy
Teoxane SA

Recruiting

Safety and Effectiveness Evaluation of TEOSYAL® TPVM Versus COMPARATOR for the Remodeling of the Lower Face (LIFTUP)

Aging | Chin Retrusion

Switzerland
Stalicla SA

Recruiting

International Multicentric Observational Study to Characterize Subpopulations of Patients With Autism Spectrum Disorder

Autism Spectrum Disorder

United States, Spain, Australia
Distalmotion SA

Recruiting

Robotic MIS With Dexter

Hysterectomy | Partial Nephrectomy | Right Colectomy

Switzerland, France, Germany
Regenosca SA

Recruiting

Bioengineered Collagen Implant for Urethral Stricture Repair

Urethral Stricture

Malaysia
Poxel SA

Not yet recruiting

Study to Assess PXL065 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)

ALD (Adrenoleukodystrophy)
Sintetica SA

Recruiting

The Efficacy and Safety of Chloroprocaine 1% and 2% in Pediatric Population

Hernia, Inguinal | Flat Foot

Italy, Spain
Novigenix SA

Completed

Relapse Markers for Colorectal Cancer (RELMA-C)

Colorectal Cancer

Belgium
Imcyse SA

Active, not recruiting

IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study (IMCY-MS-001)

Multiple Sclerosis, Relapsing-Remitting

Moldova, Republic of
Imcyse SA

Active, not recruiting

In Vitro Study of the Biological and Immunological Activity of Imotopes® Candidates on Blood Cells of Patients With Stabilized NMO

Neuromyelitis Optica

France
GeNeuro SA

Active, not recruiting

Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome

Post-COVID-19 Syndrome

Switzerland, Italy, Spain
LimFlow SA

Active, not recruiting

PROMISE International

Critical Limb Ischemia

New Zealand, Singapore, Netherlands, Germany, Austria
Cardiawave SA

Completed

Valvosoft First-In-Man Study in Severe Symptomatic Aortic Stenosis

Aortic Valve Stenosis

France, Netherlands
Cardiawave SA

Active, not recruiting

Valvosoft First-In-Human Study in Severe Symptomatic Aortic Stenosis

Aortic Valve Stenosis

Serbia
Carmat SA

Suspended

Carmat TAH Early Feasibility Study

End-stage Heart Failure

United States
Mabion SA

Completed

MabionCD20 Compared to MabThera in Lymphoma Patients (MADILYM)

Diffuse Large B-Cell Lymphoma

Serbia, Poland, Croatia, Bosnia and Herzegovina, Georgia, Moldova, Republic of, Ukraine
Teoxane SA

Completed

RHA Redensity - Perioral Rhytids

Aging | Wrinkle | Perioral Rhytids

Canada, United States
Remedee SA

Completed

Migraine STImulation Crisis of Migraine (MISTIC)

Migraine Without Aura

France
Poxel SA

Completed

Study to Assess the Safety, Tolerability, and Pharmacokinetics of PXL770 in Healthy Subjects.

NASH - Nonalcoholic Steatohepatitis

United Kingdom
ObsEva SA

Terminated

A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain

Endometriosis

United States, Canada, Puerto Rico
Imcyse SA

Completed

IMCY-T1D-002: Long-term Follow-up Study of T1D Patients Previously Treated With IMCY-0098 or Placebo (IMCY-T1D-002)

Type 1 Diabetes Mellitus

United Kingdom, Belgium, France, Lithuania, Denmark, Germany, Sweden
Aspivix SA

Completed

Usability, Safety and Efficacy of AspivixTM (Comparative Study)

IUD Insertion

Switzerland
Teoxane SA

Completed

RHA® 4 With New Anesthetic - Nasolabial Folds

Pain | Aging

United States
Teoxane SA

Completed

RHA® Redensity With New Anesthetic Agent - Perioral Rhytids

Pain | Aging

United States
Poxel SA

Completed

A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD

Nonalcoholic Fatty Liver

United States
Poxel SA

Completed

A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD

Nonalcoholic Fatty Liver

United States
ObsEva SA

Completed

Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids (PRIMROSE 2)

Uterine Fibroids | Heavy Menstrual Bleeding

United States, Bulgaria, Czechia, Hungary, Latvia, Lithuania, Poland, Romania, Ukraine
Poxel SA

Completed

Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects

Hepatic Impairment

Germany
ObsEva SA

Completed

Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function

Renal Impairment | Healthy Participants

United States
ObsEva SA

Completed

Phase 3 Placebo Controlled Study of Nolasiban to Improve Pregnancy Rates in Women Undergoing IVF/ICSI (IMPLANT2)

Infertility

Belgium, Czechia, Denmark, Estonia, Finland, Germany, Hungary, Poland, Spain
PregLem SA

Unknown

Non-interventional Study to Evaluate Long Term Safety, Prescription Management Patterns of Esmya in a Long Term Setting (Premium)

Uterine Fibroids

Spain, Belgium, Denmark, France, United Kingdom, Italy, Czechia, Germany, Romania, Latvia, Hungary, Lithuania, Netherlands, Poland, Portugal, Sweden
Wishbone SA

Unknown

Evaluation of Efficacy and Safety of Wishbone HA as Bone Graft Substitute, a Pre-market Clinical Investigation

Bone Loss in Jaw

Belgium
Poxel SA

Completed

Safety, Tolerability and PK of PXL770 in Healthy Male Subjects

Metabolic Disease

United Kingdom
Him SA

Completed

BeyondSilos - More Personalised and Coordinated Care and Improved Outcomes for Elderly Patients (BeyondSilos)

Heart Failure | Stroke | Diabetes | COPD
Pharnext SA

Completed

Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A

Charcot-Marie-Tooth Disease | Hereditary Neuropathy With Liability to Pressure Palsies | Genetic Disorders

France
Imcyse SA

Terminated

A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis (SCLEROLYM)

Multiple Sclerosis, Relapsing-Remitting

Belgium
Routin SA

Completed

Determination of the Glycemic Index and the Insulinemic Index of a Sweetener Syrup

Healthy Volunteers

France
Poxel SA

Completed

Effect of Imeglimin on QT/QTc Intervals in Healthy Subjects

Qt Interval, Variation in

United Kingdom
Xigen SA

Completed

Efficacy and Safety of XG-104 for the Treatment of Dry Eye

Dry Eye

United States
PregLem SA

Completed

PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII)

Uterine Fibroids

Belgium, Poland, Austria, Spain
PregLem SA

Completed

PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII-extension Study)

Uterine Fibroids

Poland, Spain, Austria, Belgium
PregLem SA

Completed

PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLext2)

Uterine Fibroids

Austria, Belgium, Poland, Spain
Telormedix SA

Completed

Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer

Carcinoma in Situ | Non Muscle Invasive Bladder Cancer

United States
PregLem SA

Completed

PGL5001 Proof of Concept Study in Inflammatory Endometriosis (JADE)

Endometriosis

Poland
Evolva SA

Terminated

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EV-077 in Type 2 Diabetic Subjects

Type 2 Diabetes

Germany
Cytheris SA

Completed

Safety Study of IL-7 in HIV-infected Patients (Inspire)

HIV Infections | Lymphopenia

United States, France, Canada, Italy
Cytheris SA

Unknown

Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy Alone (Eclipse 2)

Hepatitis C

France, Switzerland, Italy
Cytheris SA

Unknown

Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in Asiatic HCV Patients Resistant to Bitherapy (ECLIPSE 3)

Hepatitis C

Taiwan
Xigen SA

Completed

Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers

Inflammation

Switzerland

3

Subscribe